Mineralys Therapeutics (MLYS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $20.30, -6.19% vs the prior close of $21.64.
- Volume 1.18M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
MLYS slides 6.2% to $20.30, a 52-week low. Closed at $20.30, -6.19% vs the prior close of $21.64. Day range $20.12–$21.60, opened at $21.60.
MLYS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — MLYS slides 6.2% to $20.30, a 52-week low
- Closed at $20.30, -6.19% vs the prior close of $21.64. Day range $20.12–$21.60, opened at $21.60.
- Volume was 1.18M shares, 1.0x its 50-day average of 1.24M.
- Price is -21.7% vs its 50-day average ($25.94) and -26.6% vs its 200-day average ($27.67).
- 52-week range $20.12–$47.65; today's close sits at 1% of that range, 57.4% below the 52-week high.
Oct 15, 2026 — MLYS jumps 4.2% to $21.64
- Closed at $21.64, +4.24% vs the prior close of $20.76. Day range $20.83–$21.83, opened at $21.04.
- Volume was 1.09M shares, 0.9x its 50-day average of 1.23M.
- Price is -17.0% vs its 50-day average ($26.07) and -22.0% vs its 200-day average ($27.75).
- 52-week range $20.41–$47.65; today's close sits at 5% of that range, 54.6% below the 52-week high.
Oct 14, 2026 — MLYS dips 1.1% to $20.76, a 52-week low, 3 down days in a row
- Closed at $20.76, -1.14% vs the prior close of $21.00. Day range $20.61–$22.23, opened at $20.74.
- Volume was 1.16M shares, 1.0x its 50-day average of 1.22M.
- Price is -20.7% vs its 50-day average ($26.18) and -25.4% vs its 200-day average ($27.83).
- 52-week range $20.41–$47.65; today's close sits at 1% of that range, 56.4% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — MLYS slides 5.5% to $21.00, a 52-week low on 2.9x normal volume
- Closed at $21.00, -5.53% vs the prior close of $22.23. Day range $20.41–$22.82, opened at $22.04.
- Volume was 3.35M shares, 2.9x its 50-day average of 1.17M — unusually heavy trading.
- Price is -20.1% vs its 50-day average ($26.29) and -24.8% vs its 200-day average ($27.91).
- 52-week range $20.41–$47.65; today's close sits at 2% of that range, 55.9% below the 52-week high.
Oct 12, 2026 — MLYS slides 4.9% to $22.23
- Closed at $22.23, -4.88% vs the prior close of $23.37. Day range $22.17–$23.10, opened at $22.90.
- Volume was 1.00M shares, 0.9x its 50-day average of 1.16M.
- Price is -15.8% vs its 50-day average ($26.39) and -20.6% vs its 200-day average ($27.99).
- 52-week range $21.46–$47.65; today's close sits at 3% of that range, 53.3% below the 52-week high.
Oct 9, 2026 — MLYS jumps 4.4% to $23.37, 3 up days in a row
- Closed at $23.37, +4.42% vs the prior close of $22.38. Day range $22.36–$23.68, opened at $22.49.
- Volume was 895.30K shares, 0.8x its 50-day average of 1.15M.
- Price is -11.7% vs its 50-day average ($26.45) and -16.7% vs its 200-day average ($28.07).
- 52-week range $21.46–$47.65; today's close sits at 7% of that range, 51.0% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — MLYS rises 1.3% to $22.38 on 2.0x normal volume
- Closed at $22.38, +1.31% vs the prior close of $22.09. Day range $21.46–$22.39, opened at $22.25.
- Volume was 2.25M shares, 2.0x its 50-day average of 1.12M — unusually heavy trading.
- Price is -15.6% vs its 50-day average ($26.51) and -20.5% vs its 200-day average ($28.14).
- 52-week range $21.46–$47.65; today's close sits at 4% of that range, 53.0% below the 52-week high.
Oct 7, 2026 — MLYS rises 0.6% to $22.09
- Closed at $22.09, +0.64% vs the prior close of $21.95. Day range $21.49–$22.44, opened at $21.78.
- Volume was 989.10K shares, 0.9x its 50-day average of 1.11M.
- Price is -16.9% vs its 50-day average ($26.59) and -21.7% vs its 200-day average ($28.21).
- 52-week range $21.49–$47.65; today's close sits at 2% of that range, 53.6% below the 52-week high.
Oct 6, 2026 — MLYS slides 5.8% to $21.95, a 52-week low, 4 down days in a row
- Closed at $21.95, -5.79% vs the prior close of $23.30. Day range $21.88–$23.54, opened at $23.54.
- Volume was 1.22M shares, 1.1x its 50-day average of 1.10M.
- Price is -17.7% vs its 50-day average ($26.69) and -22.4% vs its 200-day average ($28.28).
- 52-week range $21.88–$47.65; today's close sits at 0% of that range, 53.9% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — MLYS dips 1.4% to $23.30, a 3-month low, 3 down days in a row
- Closed at $23.30, -1.40% vs the prior close of $23.63. Day range $22.97–$24.00, opened at $23.98.
- Volume was 1.08M shares, 1.0x its 50-day average of 1.10M.
- Price is -13.0% vs its 50-day average ($26.79) and -17.8% vs its 200-day average ($28.36).
- 52-week range $22.30–$47.65; today's close sits at 4% of that range, 51.1% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — MLYS dips 0.4% to $23.63, a 3-month low
- Closed at $23.63, -0.38% vs the prior close of $23.72. Day range $23.55–$24.34, opened at $24.01.
- Volume was 927.30K shares, 0.8x its 50-day average of 1.09M.
- Price is -12.0% vs its 50-day average ($26.86) and -16.9% vs its 200-day average ($28.42).
- 52-week range $22.30–$47.65; today's close sits at 5% of that range, 50.4% below the 52-week high.
MLYS latest news & SEC filings
Every SEC filing by or about MLYS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Congleton Jon sold 75,000 shares at $25.46 (≈$1.91M) on Sep 30, 2026; now holds 528,621
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 30, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Slingsby Brian Taylor sold 104,320 shares at $28.81 (≈$3.01M) on Sep 22, 2026; now holds 7,805,718
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Warren Eric converted options/RSUs into 7,438 shares at $13.24 (≈$98.48K) on Sep 21, 2026; now holds 45,838
- Warren Eric sold 7,438 shares at $28.12 (≈$209.14K) on Sep 21, 2026; now holds 38,400
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 22, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$241.07M (prior year -$43.27M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$2.85 (prior year -$0.66) (loss widened vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade MLYS
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Mar 12, 2026, Nov 10, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.34% (largest 8.5%). That is a volatile stock.
- Liquidity: about 1.37M shares (≈$27.79M) trade per day on average.
- 52-week position: $20.30 vs a range of $20.12–$47.65 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Brian Taylor Slingsby sold 104,320 shares on Sep 22, 2026.
- Latest filings: 10-Q Aug 11, 2026; 8-K Aug 11, 2026; 8-K Jun 3, 2026.
- Share count: 88.41M shares outstanding (Aug 3, 2026), +33.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
MLYS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 21.60 | 21.60 | 20.12 | 20.30 | 1.18M |
| Oct 15, 2026 | 21.04 | 21.83 | 20.83 | 21.64 | 1.09M |
| Oct 14, 2026 | 20.74 | 22.23 | 20.61 | 20.76 | 1.16M |
| Oct 13, 2026 | 22.04 | 22.82 | 20.41 | 21.00 | 3.35M |
| Oct 12, 2026 | 22.90 | 23.10 | 22.17 | 22.23 | 1.00M |
| Oct 9, 2026 | 22.49 | 23.68 | 22.36 | 23.37 | 895.30K |
| Oct 8, 2026 | 22.25 | 22.39 | 21.46 | 22.38 | 2.25M |
| Oct 7, 2026 | 21.78 | 22.44 | 21.49 | 22.09 | 989.10K |
| Oct 6, 2026 | 23.54 | 23.54 | 21.88 | 21.95 | 1.22M |
| Oct 5, 2026 | 23.98 | 24.00 | 22.97 | 23.30 | 1.08M |
| Oct 2, 2026 | 24.01 | 24.34 | 23.55 | 23.63 | 927.30K |
| Oct 1, 2026 | 25.13 | 25.34 | 23.58 | 23.72 | 1.65M |
| Sep 30, 2026 | 24.48 | 25.89 | 24.44 | 25.13 | 2.05M |
| Sep 29, 2026 | 25.39 | 25.78 | 24.43 | 24.48 | 1.72M |
| Sep 28, 2026 | 25.46 | 25.95 | 24.92 | 25.63 | 1.70M |
| Sep 25, 2026 | 26.55 | 26.70 | 25.21 | 25.86 | 1.19M |
| Sep 24, 2026 | 26.77 | 27.07 | 25.83 | 26.59 | 895.40K |
| Sep 23, 2026 | 29.36 | 29.83 | 26.62 | 26.89 | 1.48M |
| Sep 22, 2026 | 28.63 | 29.55 | 28.37 | 29.40 | 849.50K |
| Sep 21, 2026 | 28.19 | 28.44 | 27.90 | 28.31 | 701.80K |
About Mineralys Therapeutics
Mineralys Therapeutics (MLYS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in RADNOR, PA. Fiscal year ends December 31. SEC CIK 1933414.
MLYS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Srinivas Akkaraju | Director | Feb 20, 2026 |
| Jon Congleton | Chief Executive Officer | Jul 15, 2026 |
| Derek Dirocco | Director | Feb 20, 2026 |
| Alexander M Gold | Director | Feb 20, 2026 |
| Daphne Karydas | Director | Sep 17, 2026 |
| Peter Kolchinsky | Director | Mar 31, 2026 |
| Capital Management, L.P. Ra | Director | Mar 31, 2026 |
| Capital Healthcare Fund Lp Ra | Director | Mar 31, 2026 |
| Capital Nexus Fund Iii, L.P. Ra | Director | Mar 31, 2026 |
| Glenn Sblendorio | Director | Feb 20, 2026 |
| Rajeev M. Shah | Director | Mar 31, 2026 |
| Brian Taylor Slingsby | Director | Sep 24, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jon Congleton | Chief Executive Officer | Jul 15, 2026 |
| James J. Iii Ferguson | Chief Medical Officer | Aug 12, 2026 |
| Adam Scott Levy | CFO and Secretary | Feb 20, 2026 |
| David Malcom Rodman | Chief Medical Officer | Aug 12, 2026 |
| Eric Warren | Chief Commercial Officer | Sep 22, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 22, 2026 | Brian Taylor Slingsby | Sale | 104,320 | $28.81 |
| Sep 22, 2026 | Brian Taylor Slingsby | Sale | 104,320 | $28.81 |
| Sep 22, 2026 | Brian Taylor Slingsby | Sale | 104,320 | $28.81 |
| Sep 22, 2026 | Brian Taylor Slingsby | Sale | 104,320 | $28.81 |
| Sep 21, 2026 | Eric Warren | Sale | 7,438 | $28.12 |
| Sep 21, 2026 | Eric Warren | Sale | 7,438 | $28.12 |
| Sep 21, 2026 | Eric Warren | Sale | 7,438 | $28.12 |
| Sep 21, 2026 | Eric Warren | Sale | 7,438 | $28.12 |
| Sep 15, 2026 | Daphne Karydas | Sale | 3,000 | $28.58 |
| Sep 15, 2026 | Daphne Karydas | Sale | 3,000 | $28.58 |
| Sep 15, 2026 | Daphne Karydas | Sale | 3,000 | $28.58 |
| Sep 15, 2026 | Daphne Karydas | Sale | 3,000 | $28.58 |
| Aug 21, 2026 | Eric Warren | Sale | 7,437 | $25.98 |
| Aug 21, 2026 | Eric Warren | Sale | 7,437 | $25.98 |
| Aug 21, 2026 | Eric Warren | Sale | 7,437 | $25.98 |
MLYS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-154.65M | -2.29 | $-142.42M |
| Dec 31, 2024 | — | $-177.81M | -3.66 | $-166.31M |
| Dec 31, 2023 | — | $-71.90M | -1.99 | $-81.17M |
| Dec 31, 2022 | — | $-29.80M | -5.77 | $-29.22M |
Latest balance sheet: total assets $667.85M, total liabilities $116.94M, cash $138.27M (as of Jun 30, 2026).
MLYS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $27.33 |
| May 6, 2026 | 8-K Item 2.02 (results) | $30.12 |
| Mar 12, 2026 | 8-K Item 2.02 (results) | $26.99 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $44.50 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $13.51 |
| May 12, 2025 | 8-K Item 2.02 (results) | $15.01 |
| Feb 12, 2025 | 8-K Item 2.02 (results) | $10.63 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $13.38 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 21, 2024 | 8-K Item 2.02 (results) | — |
| Nov 7, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on MLYS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.